Unaudited Financial Results for the quarter ended 31-12-2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 0.7 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jeevan Scientific Technology reported a sharp jump in Q3 FY26 standalone revenue to ₹1,690.66 lakhs, up about 42% from ₹1,186.64 lakhs in Q3 FY25. Standalone profit after tax surged to ₹230.06 lakhs versus ₹32.25 lakhs a year ago. On a consolidated basis, Q3 revenue rose to ₹1,907.15 lakhs (from ₹1,250.72 lakhs) and consolidated PAT climbed to ₹240.09 lakhs (from ₹4.56 lakhs). However, for the nine-month period, consolidated PAT slipped into a loss of ₹80.86 lakhs versus a profit of ₹132.12 lakhs in 9M FY25, with most of the weakness in earlier quarters. The statutory auditor (Pavuluri & Co) issued an unmodified review conclusion. Employee cost includes ₹12.02 lakhs of ESOP expense, and new Labour Codes effective 21 Nov 2025 are flagged as not material.
Q3 shows strong recovery in revenue and profitability for this clinical research services company, which may boost sentiment in the near term. Investors should note the nine-month consolidated loss indicates the first half was weak, so the rebound is only recent and not yet a full-year trend.